INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether ARS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On June 24, 2026, ARS issued a press release “provid[ing] an update on payer access for neffy ® (epinephrine nasal spray)”, disclosing that neffy had failed to secure commercial insurance coverage. On this news, ARS’s stock price fell $2.52 per share, or 23.91%, to close at $8.02 per share on June 25, 2026.